Athira Pharma, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Athira Pharma, Inc..

News

JMP Securities Downgrades Athira Pharma (NASDAQ:ATHA) to Market Perform

Zolmax Athira Pharma (NASDAQ:ATHA - Get Free Report) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating in a research note issued to investors on...\n more…

Athira Pharma (NASDAQ:ATHA) Rating Lowered to Neutral at Rodman & Renshaw

Ticker Report Athira Pharma (NASDAQ:ATHA - Get Free Report) was downgraded by stock analysts at Rodman Renshaw from a "buy" rating to a "neutral" rating in a research note issued to investors on Wednesday...\n more…

Athira Pharma (NASDAQ:ATHA) Stock Rating Lowered by BTIG Research

Zolmax BTIG Research cut shares of Athira Pharma (NASDAQ:ATHA - Free Report) from a buy rating to a neutral rating in a report issued on Wednesday, Marketbeat reports.\nA number of other research analysts...\n more…

Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral

Ticker Report BTIG Research lowered shares of Athira Pharma (NASDAQ:ATHA - Free Report) from a buy rating to a neutral rating in a report published on Wednesday morning, MarketBeat Ratings reports. ATHA has been...\n more…

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Benzinga Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no statistical significance in key outcomes.\n more…

Rodman & Renshaw gets more bearish on Athira Pharma, downgrades shares

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…